Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
55.67
+1.05 (1.92%)
At close: Sep 10, 2026, 4:00 PM EDT
56.35
+0.68 (1.22%)
After-hours: Sep 10, 2026, 7:58 PM EDT
Scholar Rock Holding Employees
Scholar Rock Holding had 289 employees as of December 31, 2025. The number of employees increased by 93 or 47.45% compared to the previous year.
Employees
289
Change (1Y)
93
Growth (1Y)
47.45%
Revenue / Employee
n/a
Profits / Employee
-$1,413,810
Market Cap
6.78B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 289 | 93 | 47.45% |
| Dec 31, 2024 | 196 | 46 | 30.67% |
| Dec 31, 2023 | 150 | 36 | 31.58% |
| Dec 31, 2022 | 114 | -31 | -21.38% |
| Dec 31, 2021 | 145 | 26 | 21.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 433 |
| Rhythm Pharmaceuticals | 414 |
| Xenon Pharmaceuticals | 370 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Spyre Therapeutics | 125 |
SRRK News
- 12 hours ago - Scholar Rock Holding Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 1 day ago - Scholar Rock Holding Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 8 days ago - Scholar Rock receives fast track designation from FDA for apitegromab - TheFly
- 8 days ago - Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial - Business Wire
- 14 days ago - Scholar Rock to Present at Upcoming Investor Conferences - Business Wire
- 20 days ago - Scholar Rock price target raised to $64 from $58 at Wedbush - TheFly
- 20 days ago - Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission - Reuters
- 20 days ago - Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance - TheFly